



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

April 20, 2023

BSE Limited

Department of Corporate Services
Listing Department,
PJ Tower, Dalal Street,
Mumbai 400001, India
Scrip Code: **524816**

National Stock Exchange of India Ltd

Listing Department,
'Exchange Plaza', C-1, Block-G,
Bandra Kurla Complex, Bandra (East),
Mumbai 400051, India
Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Outcome of Board Meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

The Board of Directors have approved to incorporate a Subsidiary Company in Indonesia with an investment up to an amount not exceeding US\$ 3 Million (Three Million United States Dollars only), of which, initially the Company will invest US\$ 1 Million (One Million United States Dollars only) for a stake of 51% (Fifty One Percent) as capital contribution and balance will be invested by the Company as and when the funds are required by the subsidiary Company. The balance stake of 49% (Forty Nine Percent) will be held by PT. Mitra Medis Exim (MME), that belongs to Mitra Jaya Group which is a 40 year old multi-diversified group, as the co-promoter of the proposed subsidiary Company. MME is in the business of distribution for active pharmaceutical ingredients and excipients for the end users in Indonesia.

The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid acquisition is enclosed as Annexure - I

This is for your information and records.

Meeting commenced at 10.00 a.m. and concluded at 10.40 a.m.

Yours faithfully

For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl.: as above

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Details of Investment
A	Name of the target entity, details in brief such as size, turnover etc.	<p>1) Name of the target entity</p> <p>PT. NATCO Lotus Farma (yet to be incorporated in Indonesia)</p> <p>2) Details in brief such as size, turnover etc.</p> <p>PT. NATCO Lotus Farma will be engaged in selling of pharmaceuticals in Indonesia</p>
B	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No
C	Industry to which the entity being acquired belongs	Pharmaceuticals
D	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Objective is to enter new geographies for growth and increased profitability
E	Brief details of any governmental or regulatory approvals required for the acquisition	ODI under FEMA Regulations
F	Indicative time period for completion of the acquisition;	April 19, 2024
G	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
H	Cost of acquisition or the price at which the shares are acquired	Initial capital contribution of US\$ 1 million
I	Percentage of shareholding / control acquired and / or number of shares acquired	51%

Sl. No.	Particulars	Details of Investment
J	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>1. Brief background:</p> <p>PT. NATCO Lotus Farma will be engaged in selling of pharmaceuticals in Indonesia.</p> <p>2. Line of business:</p> <p>Pharmaceuticals</p> <p>3. Date of incorporation:</p> <p>NA</p> <p>4. Turnover of last 3 years:</p> <p>NA</p> <p>5. Country in which the acquired entity will have presence:</p> <p>Indonesia</p>